[HTML][HTML] The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after …

AD Hartkopf, FA Taran, M Wallwiener… - Breast Cancer …, 2013 - Springer
AD Hartkopf, FA Taran, M Wallwiener, C Hagenbeck, C Melcher, N Krawczyk, M Hahn…
Breast Cancer Research, 2013Springer
Introduction Neoadjuvant systemic therapy of primary breast cancer (PBC) patients offers the
possibility to monitor treatment response. However, patients might have metastatic relapse
despite achieving a pathologic complete response (pCR). This indicates that local response
to therapy must not be representative for systemic treatment efficacy. Therefore, the aim of
this study was to compare local response with systemic tumor cell dissemination by
determining the presence of disseminated tumor cells (DTCs), including apoptotic tumor …
Introduction
Neoadjuvant systemic therapy of primary breast cancer (PBC) patients offers the possibility to monitor treatment response. However, patients might have metastatic relapse despite achieving a pathologic complete response (pCR). This indicates that local response to therapy must not be representative for systemic treatment efficacy. Therefore, the aim of this study was to compare local response with systemic tumor cell dissemination by determining the presence of disseminated tumor cells (DTCs), including apoptotic tumor cells, in the bone marrow (BM) of PBC patients after neoadjuvant chemotherapy (NACT).
Methods
DTCs were detected by immunocytochemistry (pancytokeratin antibody A45-B/B3) and cytomorphology (DTC status). The presence of apoptotic tumor cells was determined by using the M30 antibody (M30 status). This antibody detects a neo-epitope that is expressed only during early apoptosis.
Results
BM aspirates from 400 PBC patients that had completed NACT were eligible for this study. Of these, 167 (42%) patients were DTC positive (DTC status). The M30 status was investigated in 308 patients. Apoptotic (M30-positive) tumor cells were detected in 89 (29%) of these. Whereas the DTC status was not correlated (P = 0.557) to local treatment response (that is, pCR or a clinical complete/partial response), the presence of M30-positive tumor cells was significantly higher in patients that responded to therapy (P = 0.026). Additionally, DTC-positive patients were at an increased risk for disease relapse (hazard ratio, 1.87; 95% CI, 1.11 to 3.15; P = 0.019).
Conclusion
The presence of DTC is independent of therapy response of the primary tumor. As patients that are DTC positive after NACT have an unfavorable outcome, they might benefit from additional systemic treatment.
Springer